- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04203173
- Original Trial
Financial Incentives And Nurse Coaching to Enhance Diabetes Outcomes (FINANCE-DM)-1 (FINANCE-DM)
May 29, 2026 updated by: Leonard Ehianu Egede, State University of New York at Buffalo
Financial Incentives And Nurse Coaching to Enhance Diabetes Outcomes - FINANCE-DM
The objective of this protocol is to answer the questions: 1) Are financial incentives layered upon nurse education and home telemonitoring superior to nurse education and home telemonitoring alone in improving metabolic control long term?
2) Are the effects of financial incentives on metabolic control sustained once the incentives are withdrawn?
and 3) Are financial incentives efficacious within and consistent across racial/ethnic groups?
This study provides a unique opportunity to address these gaps in the literature.
Investigators propose a randomized controlled trial to test the efficacy of a Financial Incentives And Nurse Coaching to Enhance Diabetes Outcomes (FINANCE-DM) intervention comprised of: 1) nurse education, 2) home telemonitoring, and 3) structured financial incentives; compared to an active control group (nurse education and home telemonitoring alone).
The study also will evaluate whether intervention effects are sustained 6 months after the financial incentives are withdrawn (i.e.
18 months post randomization); and whether the intervention is differentially efficacious across racial/ethnic groups.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
Study Overview.
The overarching aim of this proposal is to test the efficacy of structured financial incentives intervention (FINANCE-DM) comprised of: 1) nurse education, 2) home telemonitoring, and 3) structured financial incentives; compared to an active control group (nurse education and home telemonitoring alone) on glycemic control.
The study also will evaluate whether intervention effects are sustained 6 months after the financial incentives are withdrawn (i.e.
18 months post randomization); and whether the intervention is differentially efficacious across racial/ethnic groups.
Equal number of patients from three racial/ethnic groups (150 Whites, 150 AAs and 150 HAs, total sample of 450) will be randomized to FINANCE-DM intervention (n=225) or an active comparator group (n=225), so that within each racial/ethnic group, half (75 patients) will be randomized to the FINANCE-DM intervention group and the other half (75 patients) will be randomized to the active comparator group.
Primary aims are to test overall efficacy across combined racial/ethnic groups; efficacy within racial/ethnic groups and cost effectiveness for the primary endpoint (glycemic control).
Secondary aim is to test efficacy on secondary endpoints including BP, LDL, QOL and self-care behaviors.
Each patient will be followed for 12 months (long-term effect) and 18 months (sustainability effect), with study visits at baseline, 3, 6, 9, 12 and 18 months.
The FINANCE-DM intervention is comprised of: 1) nurse education, 2) home telemonitoring, and 3) structured financial incentives.
The active comparator group will receive the same nurse education and home telemonitoring intervention as the FINANCE-DM group, on the same schedule, and for the same duration .
The only difference is that participants will not receive structured financial incentives.
Study Type
Interventional
Enrollment (Estimated)
450
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
Buffalo, New York, United States, 14203
- State University of New York at Buffalo
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age >=21 years;
- Clinical diagnosis of T2DM and HbA1c >=8% at the screening visit;
- Self-identified as White, AA or HA;
- Subject must be willing to use the FORA monitoring system for 12 months;
- Subjects must have access to a landline, Ethernet or cellphone for FORA data uploads for the study period; and 6) Ability to communicate in English.
Exclusion Criteria:
- Mental confusion on interview suggesting significant dementia;
- Participation in other diabetes clinical trials;
- Alcohol or drug abuse/dependency;
- Active psychosis or acute mental disorder; and
- Life expectancy <18 months.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: FINANCE-DM Intervention
The FINANCE-DM intervention is comprised of: 1) nurse education, 2) home telemonitoring, and 3) structured financial incentives.
|
The FINANCE-DM intervention is comprised of: 1) nurse education, 2) home telemonitoring, and 3) structured financial incentives.
Patients randomized to FINANCE-DM will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day.
BG and BP will be measured daily and results will be uploaded to a secure server.
A nurse educator will review the glucose and BP readings and use them to tailor and reinforce behavior change during weekly telephone-delivered diabetes education and skills training session.
Participants will also receive financial rewards for: 1) uploading glucose measurements; 2) participating in telephone delivered educational sessions; and 3) absolute percentage drops in HbA1c from baseline at each 3-month follow-up intervals.
|
|
Active Comparator: TIDES Intervention
Patients randomized to the active comparator group will be assigned the FORA 2-in-1 Telehealth System.
A nurse educator will review the glucose and BP readings and use them to tailor and reinforce behavior change.
|
Patients randomized to the active comparator group will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day.
BG and BP will be measured daily and results will be uploaded to a secure server.
A nurse educator will review the glucose and BP readings and use them to tailor and reinforce behavior change during weekly telephone-delivered diabetes education and skills training session.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glycemic control (HbA1c)
Time Frame: Change from baseline HbA1c at 12 months post intervention follow-ups
|
Blood specimens (10cc of blood) will be obtained by trained phlebotomists or nurse for HbA1c.
|
Change from baseline HbA1c at 12 months post intervention follow-ups
|
|
Resource Utilization and Cost
Time Frame: Change from baseline resource utilization and cost at at 12 months post-intervention follow-ups
|
Previously validated questions on resource utilization will be administered.
The questionnaires capture information on hospitalizations, physician/professional visits, and medications.
|
Change from baseline resource utilization and cost at at 12 months post-intervention follow-ups
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
LDL-Cholesterol
Time Frame: Change from baseline cholesterol at at 12 months post intervention follow-ups
|
About 10cc of blood will be drawn by trained phlebotomists and sent to the lab for LDL-Cholesterol.
|
Change from baseline cholesterol at at 12 months post intervention follow-ups
|
|
Quality of Life as measured by SF-12
Time Frame: Change from baseline quality of life measure at at 12 months post intervention follow-ups
|
The SF-12 (Ware 1996) is a valid and reliable instrument to measure functional status and reproduces 90% of the variance in PCS-36 and MCS-36 scores.
|
Change from baseline quality of life measure at at 12 months post intervention follow-ups
|
|
Systolic and Diastolic Blood Pressure
Time Frame: Change from baseline blood pressure at at 12 months post intervention follow-ups
|
Blood pressure readings will be obtained using automated BP monitors (OMRON IntelliSenseTM HEM-907XL).
The device will be programmed to take 3 readings at 2-minute intervals, and give an average of the 3 BP readings.
|
Change from baseline blood pressure at at 12 months post intervention follow-ups
|
|
Self-Care Behavior
Time Frame: Change from baseline self-care at at 12 months post intervention follow-ups
|
Behavioral skills will be assessed with the Summary of Diabetes Self-Care Activities (SDSCA) scale (Toobert 2000), a brief, validated questionnaire of diabetes self-care. .
|
Change from baseline self-care at at 12 months post intervention follow-ups
|
|
Self-Care Behavior Brooks Medication Adherence Scale (BMAS)
Time Frame: Change from baseline self-care at at 12 months post intervention follow-ups
|
Medication Adherence will be measured with the 6-item validated self-report Brooks Medication Adherence Scale (BMAS) (Brooks 1994).
Each of 6 items measures a specific medication-taking behavior.
|
Change from baseline self-care at at 12 months post intervention follow-ups
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Leonard E Egede, MD, MS, State University of New York at Buffalo
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2019
Primary Completion (Actual)
June 30, 2025
Study Completion (Estimated)
June 30, 2026
Study Registration Dates
First Submitted
November 26, 2019
First Submitted That Met QC Criteria
December 17, 2019
First Posted (Actual)
December 18, 2019
Study Record Updates
Last Update Posted (Actual)
June 2, 2026
Last Update Submitted That Met QC Criteria
May 29, 2026
Last Verified
May 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1R01DK120861 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
University of North Carolina, Chapel HillAmerican Heart AssociationRecruitingType 2 Diabetes | Nutrition | Diabetes Type 2 | T2DM (Type 2 Diabetes Mellitus) | Diabetes Mellitis | T2DM | Diabetes EducationUnited States
-
Kaiser PermanenteThe Permanente Medical GroupEnrolling by invitationType 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes (T2D)United States
-
Endogenex, Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes Mellitus | Type 2 Diabetes | Type2diabetes
-
ENBIOSIS BIOTECHNOLOGIESAydin Adnan Menderes University; Izmir University of Economics; Buca Seyfi Demirsoy... and other collaboratorsRecruitingType 2 Diabetes | Diabetes Mellitus Type 2Turkey (Türkiye)
-
University of MiamiSexual Medicine Society of North America Inc.Not yet recruitingType 2 Diabetes | Type 2 Diabetes (T2DM)United States
-
Endogenex, Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type2Diabetes
-
Medical University of GrazCompletedType 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes, Insulin RequiringAustria
-
University of SalamancaUniversity of Salamanca; Instituto Piaget; Escola Superior de Tecnologia da Saúde...Enrolling by invitationType 2 Diabetes Mellitus | Aging | Hyperglycemia Due to Type 2 Diabetes MellitusPortugal
-
Instituto Nacional de Ciencias Medicas y Nutricion...Active, not recruiting
-
Steno Diabetes Center CopenhagenRecruitingDiabetes | Cognitive Impairment | Type 2 Diabetes | Diabetes Mellitus Type 2 | Cognitive Decline | Type 2 Diabetes Mellitus (T2DM)Denmark
Clinical Trials on FINANCE-DM
-
NMP Medical Research InstituteSonal Foundation, India; Macmillan Research Group UK; Vinita Nursing Home, IndiaCompletedEffect of a Micro-finance-based Intervention for the Prevention of Intimate-partner Violence and HIVHIV | Domestic Violence | AIDSIndia
-
Johns Hopkins UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedMental Health DisordersCongo
-
State University of New York at BuffaloActive, not recruiting
-
Desentum OyCompletedBirch Pollen AllergyFinland
-
Sun Yat-sen UniversityRecruitingDeep Learning | 3D-reconstruction | Patient Privacy | Digital MedicineChina
-
Desentum OyCompleted
-
Neurovalens Ltd.University College Dublin; Clinical Trial Mentors; CS LifescienceCompletedType 2 DiabetesUnited States, Ireland
-
National University, SingaporeTsao Foundation SingaporeActive, not recruiting
-
Emory UniversityNational Institute of Nursing Research (NINR); Atlanta VA Medical Center; Atlanta...CompletedHeart Failure | Diabetes MellitusUnited States
-
Diabetes Foundation, IndiaMinistry of Science and Technology, IndiaNot yet recruitingDiabetes Mellitus | PreDiabetes | Diet Habit